News | April 06, 2021
Panacea to produce 100 mn doses of Sputnik V vaccine
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
India produces 60% of the world’s vaccine
The vaccine was 85 percent effective in preventing severe disease across all regions.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Subscribe To Our Newsletter & Stay Updated
